EA200301135A1 - Применение галантамина для лечения патологических проявлений центральной нервной системы, вызванных интоксикацией психотропными веществами - Google Patents

Применение галантамина для лечения патологических проявлений центральной нервной системы, вызванных интоксикацией психотропными веществами

Info

Publication number
EA200301135A1
EA200301135A1 EA200301135A EA200301135A EA200301135A1 EA 200301135 A1 EA200301135 A1 EA 200301135A1 EA 200301135 A EA200301135 A EA 200301135A EA 200301135 A EA200301135 A EA 200301135A EA 200301135 A1 EA200301135 A1 EA 200301135A1
Authority
EA
Eurasian Patent Office
Prior art keywords
substances
disorders
galantamine
psychotropic
treatment
Prior art date
Application number
EA200301135A
Other languages
English (en)
Russian (ru)
Inventor
Клаус Опиц
Йохим Моорманн
Томас Хилле
Франк Бехер
Original Assignee
Хф Арцнаймиттельфоршунг Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7682409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200301135(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Хф Арцнаймиттельфоршунг Гмбх filed Critical Хф Арцнаймиттельфоршунг Гмбх
Publication of EA200301135A1 publication Critical patent/EA200301135A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA200301135A 2001-04-24 2002-04-18 Применение галантамина для лечения патологических проявлений центральной нервной системы, вызванных интоксикацией психотропными веществами EA200301135A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10119862A DE10119862A1 (de) 2001-04-24 2001-04-24 Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
PCT/EP2002/004277 WO2002085370A1 (de) 2001-04-24 2002-04-18 Verwendung von galanthamin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen

Publications (1)

Publication Number Publication Date
EA200301135A1 true EA200301135A1 (ru) 2004-04-29

Family

ID=7682409

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301135A EA200301135A1 (ru) 2001-04-24 2002-04-18 Применение галантамина для лечения патологических проявлений центральной нервной системы, вызванных интоксикацией психотропными веществами

Country Status (27)

Country Link
US (1) US8207159B2 (pl)
EP (1) EP1383507B1 (pl)
JP (1) JP2004531533A (pl)
KR (1) KR20040005934A (pl)
CN (1) CN100400043C (pl)
AR (1) AR033468A1 (pl)
AT (1) ATE378052T1 (pl)
AU (1) AU2002308148B2 (pl)
BR (1) BR0209126A (pl)
CA (1) CA2444818C (pl)
CZ (1) CZ20032789A3 (pl)
DE (2) DE10119862A1 (pl)
DK (1) DK1383507T3 (pl)
EA (1) EA200301135A1 (pl)
ES (1) ES2296990T3 (pl)
HK (1) HK1062401A1 (pl)
HU (1) HUP0401123A3 (pl)
IL (2) IL158382A0 (pl)
MX (1) MXPA03009765A (pl)
NO (1) NO20034740L (pl)
NZ (1) NZ529004A (pl)
PL (1) PL207525B1 (pl)
PT (1) PT1383507E (pl)
SK (1) SK287235B6 (pl)
TW (1) TWI329512B (pl)
WO (1) WO2002085370A1 (pl)
ZA (1) ZA200308004B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004216360B2 (en) * 2003-02-27 2009-09-17 Eisai R & D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
FR2930891B1 (fr) 2008-05-06 2010-09-24 Biocodex Composes anti-amnesiants et compositions pharmaceutiques les comprenant
EP2586436A1 (en) 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
US20180200259A1 (en) * 2015-05-18 2018-07-19 Synaptec Development Llc GALANTAMINE CLEARANCE OF AMYLOID ß
US20230202978A1 (en) 2022-03-04 2023-06-29 Reset Pharmaceuticals, Inc. Co-crystal or salt

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1193061B (de) 1961-12-20 1965-05-20 Vni Chimiko Pharmazewtitschesk Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3843239C1 (pl) 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5015645A (en) * 1989-10-19 1991-05-14 Ciba-Geigy Corporation Tetracyclic pyrrole lactam derivatives
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
US5965571A (en) * 1996-08-22 1999-10-12 New York University Cholinesterase inhibitors for treatment of Parkinson's disease
US5932557A (en) * 1997-08-12 1999-08-03 Mustafa; S. Jamal Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments
CN1240384C (zh) * 1999-11-04 2006-02-08 美国爱科赛尔制药有限公司 石杉碱经皮给药制剂
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders

Also Published As

Publication number Publication date
DE10119862A1 (de) 2002-11-07
SK287235B6 (sk) 2010-04-07
PL207525B1 (pl) 2010-12-31
KR20040005934A (ko) 2004-01-16
BR0209126A (pt) 2004-07-27
ES2296990T3 (es) 2008-05-01
SK13152003A3 (sk) 2004-04-06
CZ20032789A3 (en) 2004-05-12
EP1383507A1 (de) 2004-01-28
MXPA03009765A (es) 2005-04-19
HK1062401A1 (en) 2004-11-05
DK1383507T3 (da) 2008-03-17
AR033468A1 (es) 2003-12-17
IL158382A (en) 2009-09-01
ATE378052T1 (de) 2007-11-15
US20040116406A1 (en) 2004-06-17
PT1383507E (pt) 2008-02-20
CN1505516A (zh) 2004-06-16
CA2444818A1 (en) 2002-10-31
CA2444818C (en) 2009-06-16
TWI329512B (en) 2010-09-01
IL158382A0 (en) 2004-05-12
NO20034740D0 (no) 2003-10-23
WO2002085370A1 (de) 2002-10-31
US8207159B2 (en) 2012-06-26
AU2002308148B2 (en) 2006-11-02
EP1383507B1 (de) 2007-11-14
HUP0401123A2 (hu) 2004-09-28
JP2004531533A (ja) 2004-10-14
DE50211207D1 (de) 2007-12-27
CN100400043C (zh) 2008-07-09
NO20034740L (no) 2003-10-23
NZ529004A (en) 2007-01-26
HUP0401123A3 (en) 2008-01-28
ZA200308004B (en) 2004-02-11
PL366840A1 (pl) 2005-02-07

Similar Documents

Publication Publication Date Title
EA200200766A1 (ru) Замещенные арилпиразины
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
CY1111206T1 (el) Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
BRPI0407910A (pt) usos de compostos para prevenção, tratamento ou diagnóstico, em um indivìduo, de um distúrbio de agregação de proteìna
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
ATE494890T1 (de) Alpha-aminoamid-derivate zur behandlung von suchtstörungen
EP2426115A3 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
CL2007002705A1 (es) Composicion farmaceutica oftalmica autopreservada que comprende 0,04 a 0,9 mm de iones zinc donde la concentracion de aniones tamponantes es menor que 15 mm.
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
EA200970817A1 (ru) Лекарственная форма, содержащая 1{6-[(3-циклобутил-2,3,4,5-тетрагидро-1н-3-бензазепин-7-ил)окси]-3-пиридинил}-2-пирролидинон или его соль и стабилизатор, который уменьшает его деградацию
TW200642690A (en) Composition for treating central nervous system disorders
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
IL169889A0 (en) Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin
EA200301135A1 (ru) Применение галантамина для лечения патологических проявлений центральной нервной системы, вызванных интоксикацией психотропными веществами
EA200301134A1 (ru) Применение дезоксипеганина для лечения патологических проявлений центральной нервной системы, вызванных интоксикацией психотропными веществами
WO2007129221A3 (en) Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation
WO2004035606A3 (en) Bace binding peptides and uses thereof
NO20081739L (no) Carbazole derivatives as functional 5-HT6 ligands
BR9915572A (pt) Processo de tratamento de doença de célula falciforme e talassemia
MA28330A1 (fr) Derives de morpholine en tant qu'inhibiteurs de la recapture de la norepinephrine
WO2004069197A3 (en) Novel substituted 2,3-benzodiazepine derivatives
EA200501052A1 (ru) Способ лечения поведенческих расстройств
BR0308753A (pt) Método para produzir pseudo-ilhotas
TH64669A (th) สารประกอบชนิดใหม่
TH71491A (th) สารประกอบชนิดใหม่